Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience announced today that its preliminary fiscal second quarter revenues are expected to be down nearly 12 percent year over year driven by a decline in revenues in its diagnostics segment.

For fiscal Q2 2019, the company said that revenues are anticipated to be approximately $50.0 million compared to $56.5 million a year ago. The analysts' average estimate is $56.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.